Publication Name	World Journal of Gastroenterology
Manuscript ID	12098
Country	Türkiye

Received	2014-06-22 12:46
Peer-Review Started	2014-06-22 17:43
To Make the First Decision	2014-07-09 12:08
Return for Revision	2014-07-17 16:07
Revised	2014-07-23 02:03
Second Decision	2014-09-05 16:49
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-09-05 17:19
Articles in Press	2014-09-05 17:28
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-02-03 19:57
Publish the Manuscript Online	2015-02-11 16:38

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Hepatitis B reactivation and timing for prophylaxis
Manuscript Source	Unsolicited Manuscript
All Author List	Nazan Tuna and Oguz Karabay
Funding Agency and Grant Number
Corresponding Author	Nazan Tuna, MD, department of Infectious Diseases, faculty of Medicine, Sakarya University, Adnan menderes Bulvarı, 54100 Sakarya, Turkey. tunanazan@hotmail.com
Key Words	Hepatitis B; Immunotherapy; Hepatitis B reactivation; Antiviral prophylaxis; Inadequate time; Lamivudine
Core Tip	Lamivudine is the most commonly used drug in hepatitis B virus (HBV) reactivation pro-phylaxis. However, if Rituximab is included in the immunochemotherapy regime, HBV reactivation is expected to occur more severely.
Publish Date	2015-02-11 16:38
Citation	Tuna N, Karabay O. Hepatitis B reactivation and timing for prophylaxis. World J Gastroenterol 2015; 21(7): 2263-2264
URL	http://www.wjgnet.com/1007-9327/full/v21/i7/2263.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i7.2263

Full Article (PDF)	WJG-21-2263.pdf
Full Article (Word)	WJG-21-2263.doc
Manuscript File	12098-Review.doc
Answering Reviewers	12098-Answering reviewers.pdf
Copyright License Agreement	12098-Copyright assignment.pdf
Peer-review Report	12098-Peer reviewers.pdf
Scientific Misconduct Check	12098-CrossCheck.jpg
Scientific Editor Work List	12098-Scientific editor work list.pdf